---
title: "XJZY: The company's dexamethasone acetate tablets have passed the consistency evaluation of generic drugs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254124280.md"
description: "On August 22, XJZY announced that the company recently received the \"Drug Supplement Application Approval Notice\" issued by the National Medical Products Administration regarding Dexamethasone Acetate Tablets. The company's Dexamethasone Acetate Tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Dexamethasone Acetate Tablets are corticosteroids primarily used for allergic and autoimmune inflammatory diseases, such as connective tissue diseases, severe bronchial asthma, dermatitis and other allergic diseases, ulcerative colitis, acute leukemia, malignant lymphoma, etc"
datetime: "2025-08-22T08:41:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254124280.md)
  - [en](https://longbridge.com/en/news/254124280.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254124280.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/254124280.md) | [繁體中文](https://longbridge.com/zh-HK/news/254124280.md)


# XJZY: The company's dexamethasone acetate tablets have passed the consistency evaluation of generic drugs

On August 22, XJZY announced that the company recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration regarding Dexamethasone Acetate Tablets. The company's Dexamethasone Acetate Tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Dexamethasone Acetate Tablets are a type of adrenal corticosteroid, mainly used for allergic and autoimmune inflammatory diseases, such as connective tissue diseases, severe bronchial asthma, dermatitis and other allergic diseases, ulcerative colitis, acute leukemia, malignant lymphoma, etc

### Related Stocks

- [XJZY (002332.CN)](https://longbridge.com/en/quote/002332.CN.md)

## Related News & Research

- [Nine out of 10 bets this fund manager made outperformed over the past year. Here's his next two plays.](https://longbridge.com/en/news/277192065.md)
- [Changchun High-Tech Industry Files Clinical Trial Application for GenSci161 Injection](https://longbridge.com/en/news/277574518.md)
- [January CPI Revives Rate-Cut Hopes; Gold and Silver Rebound, But Is the Bull Run Intact?](https://longbridge.com/en/news/277142018.md)
- [Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China](https://longbridge.com/en/news/277568022.md)
- [SSY Group's Respiratory Drug Approved for Production in China](https://longbridge.com/en/news/277561555.md)